A single droplet digital PCR for ESR1 activating mutations detection in plasma

Emmanuelle Jeannot, Lauren Darrigues, Marc Michel, +13

Oncogene

EngineeringNatural SciencesMolecular BiologyDna ReplicationMutations Detection +5

Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie

Clémence Basse, Claire Morel, Marie Alt, +31

ESMO Open

Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics)

Julien Vibert, Gaëlle Pierron, Camille Benoist, +11

Journal of Molecular Diagnostics

Tumor HeterogeneityMedicinePathologyRna SequencingCancer Genomics +6

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Liang Xu, Adrien Briaux, Véronique Becette, +12

Journal of Hematology & Oncology

Highly Sensitive Detection Method of Retinoblastoma Genetic Predisposition and Biomarkers

Jessica Le Gall, Catherine Dehainault, Camille Benoist, +14

Journal of Molecular Diagnostics

MedicineGeneticsPathologyMolecular DiagnosticsCancer Research +1

Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease

Joanna Cyrta, Arnaud Gauthier, Marie Karanian, +23

The American Journal of Surgical Pathology

Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS

Céline Callens, François‐Clément Bidard, Anaïs Curto-Taribo, +19

Analytical Chemistry

E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma

Lounes Djerroudi, Amel Bendali, Laetitia Fuhrmann, +14

Modern Pathology

Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis

Irène Jiménez, Éléonore Frouin, Mathieu Chicard, +21

European Journal of Cancer

Tumor BiologyTumor Dna AnalysisOncologyCancer DetectionMedicine +4

Combination of COX-2 expression and <i>PIK3CA</i> mutation as prognostic and predictive markers for celecoxib treatment in breast cancer

Sandrine Tury, Véronique Becette, Franck Assayag, +7

Oncotarget

Breast OncologyChemoprevention StrategyPathologyCox-2 ExpressionTumor Biology +14